Rethinking the User Requirements Specification in RTSM Software

The User Requirements Challenge in Modern RTSM

In Randomization and Trial Supply Management (RTSM), the User Requirements Specification (URS) plays a critical role in ensuring the system aligns with your protocol. It’s where the design becomes real, capturing everything from how screening modules behave to how drug supply is calculated and dispensed.

For large pharma Sponsors, this process is well-supported. Dedicated RTSM project managers, clinical supply leads, and QA specialists can review every line of a long and detailed URS and track every functional requirement across teams.

But for small and mid-sized biotechs, that model doesn’t scale. Teams are lean, timelines are tight, and there may be limitations in knowing what to look for across hundreds of pages that covers both protocol specifics as well as RTSM base-system behavior. The expectation to review every detail is still there, but the resources often aren’t.

That’s where the challenge lies for smaller Sponsors. You still need a URS, just like large pharma, but you don’t have the luxury of weeks-long document reviews or a dedicated team. What you need is the same outcome: clear documentation of how the system should behave, but you need a smarter, more focused process to get there.

With upfront planning, a well-structured URS process can clarify expectations, reduce downstream risk, and make it easier for every stakeholder to engage, whether they want a quick overview or a deep dive into platform logic.

The Temptation of the “Build-First, Document-Later” Shortcut

Some RTSM software vendors try to skip the URS altogether. Their model? Take your protocol, configure the system in a sandbox, and generate a pseudo-URS after the fact, based on what was built.

On the surface, that may sound even faster than a streamlined spec. But in practice, it introduces real risk.

In regulated environments, you don’t start with a finished system and reverse-engineer the documentation. You define what needs to be built first, then use that specification to guide configuration, testing, and approval.

Without that upfront URS, there’s no record of why the system behaves the way it does. And in RTSM software where most of the logic is behind the scenes (in dose algorithms, validation checks, and complex supply triggers), you’re relying on memory or assumptions if anything ever needs to be explained, audited, or changed later.

It’s faster, but fast at the expense of quality and traceability.

User Requirements Specification: Structured and Streamlined

Efficiency in RTSM setup doesn’t mean cutting corners, and it certainly doesn’t mean skipping the foundational planning that ensures your system aligns with the protocol. Some Sponsors genuinely require what could be a several-hundred-page URS, and for those Sponsors, that level of detail is essential. Others need a more streamlined version that’s easier to digest and manage with leaner teams.

What matters most is having a URS process that flexes, one that fits the complexity of the study and the structure of the Sponsor team, without compromising clarity or quality.

A modern URS process should be structured, scalable, and thoughtfully led. The RTSM provider’s job is to guide stakeholders through the requirements gathering and documentation in a way that supports confident decision-making. That means engaging the right people at the right time, and presenting the right level of detail, whether that’s a deep dive into platform behavior or a focused review of study-specific logic.

It starts by centering the URS on the things that vary from study to study: protocol nuances, dosing rules, data formats, and stakeholder-critical workflows. These targeted reviews help teams validate what matters to their role, while bypassing system-wide documentation that may not be relevant. The result is a more effective URS cycle, better alignment before UAT, and fewer surprises downstream.

Of course, even when a Sponsor opts for a lighter-weight spec, that doesn’t mean the details disappear. A strong RTSM provider will still capture all platform-level behaviors, defaults, and validation logic, just in a format that’s available as needed. When a UAT issue arises, an audit is conducted, or a change order is requested, the full documentation should be there to back it up.

This right-sizing of the URS makes it easier to bring stakeholders to the table, clarify expectations early, and build trust in how the system will behave. It’s like building a house: You don’t sketch out the blueprints after the roof is on, and you don’t need to hand everyone the full architectural manual if you’re only customizing a few rooms. But you do need to know it’s available when you need it.

URS: Getting it Right

A full User Requirements Specification still has its place, especially for Sponsors with the time, structure, and internal expertise to review every detail. Though for growing biotechs with leaner teams, the traditional model often creates friction that slows the process down.

Korio offers a modern and flexible approach that bridges both realities. Whether you need a focused, study-specific specification or a deeply detailed system-wide document, our process ensures you get the right level of clarity without unnecessary overhead. The foundational details are always captured, traceable, and ready when needed.

With experienced RTSM project managers guiding the process, a dynamic documentation structure, and a platform built for transparency, Korio helps Sponsors move faster, plan smarter, and stay aligned from day one. No matter how complex the study, you get the confidence of knowing the details are covered.

Be Ready for the Trials Ahead with Korio

Frequently Asked Questions

What is a User Requirements Specification (URS) in RTSM software?

A User Requirements Specification is the document that defines how RTSM software must behave for a specific clinical trial before the system is configured. It covers screening and randomization logic, visit schedules, dosing rules, dispensing behavior, supply triggers, and integrations with other clinical trial systems.

In regulated clinical trials, the URS is the reference point that configuration, testing, and approval are traced back to. It answers the question an auditor eventually asks: why does the system behave this way?

Most of what RTSM software does in a clinical trial is not visible on screen. Dose calculations, validation checks, and resupply triggers run behind the interface, so the only durable record of intended behavior is the specification written before the build.

Without that record, explaining or changing the system depends on individual memory. That becomes a problem during an audit, during a protocol amendment, or when the person who configured the study moves to another role.

Some RTSM software vendors configure the system in a sandbox from the protocol and generate the specification afterward, based on what was built. The document then describes the build rather than defining it.

In a regulated clinical trial, that inverts the order that makes documentation useful. A specification written after configuration cannot catch a misunderstanding, because the misunderstanding is already in the system. It also removes the record of intent that quality and regulatory reviewers rely on.

A several-hundred-page URS assumes a review team that can work through it line by line. Large pharma Sponsors have dedicated RTSM project managers, clinical supply leads, and QA specialists to do that. Lean biotech teams running the same clinical trial complexity do not.

The document also covers two different things at once: study-specific protocol behavior and RTSM base-system behavior that is identical across every clinical trial the vendor runs. Reviewing both under go-live pressure means the review often happens because the timeline requires it, not because every page received attention.

A right-sized URS focuses the Sponsor’s review on what varies from clinical trial to clinical trial: protocol nuances, dosing rules, data formats, and the workflows each stakeholder owns. A clinical supply lead reviews resupply and expiry logic. A data manager reviews formats and integrations.

The rest does not disappear. Platform-level behavior, defaults, and validation logic are still documented, in a format available on demand rather than sent to every reviewer by default.

No, provided the underlying documentation exists and can be produced. The distinction is between what a Sponsor reviews and what a vendor maintains.

Three moments test this: a UAT issue that needs an explanation, a regulatory audit or inspection, and a change order after go-live. In each one, the full record of platform behavior and study configuration has to be available.

UAT tests the system against the specification. When the URS is vague or was reviewed superficially, misunderstandings surface during UAT instead of during requirements gathering, which is the more expensive place to find them.

Targeted review by the people who own each workflow produces fewer open questions going into UAT and fewer surprises after the clinical trial goes live.